DRD2 and schizophrenia: Genetic evidence for disruption of neuromodulators is so far restricted to dopamine, with a genome-wide significant GWAS signal localized to DRD2 (Schizophrenia Working Group of the Psychiatric Genomics Consortium, 2014).